204 related articles for article (PubMed ID: 30638934)
1. Nuclear TAZ activity distinctly associates with subtypes of non-small cell lung cancer.
Wang Y; Han Y; Guo Z; Yang Y; Ren T
Biochem Biophys Res Commun; 2019 Feb; 509(3):828-832. PubMed ID: 30638934
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
[TBL] [Abstract][Full Text] [Related]
3. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
Zhou S; Wang P; Su X; Chen J; Chen H; Yang H; Fang A; Xie L; Yao Y; Yang J
PLoS One; 2017; 12(10):e0187356. PubMed ID: 29088286
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
Yu H; Pang Z; Li G; Gu T
J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
6. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.
Schlensog M; Magnus L; Heide T; Eschenbruch J; Steib F; Tator M; Kloten V; Rose M; Noetzel E; Gaisa NT; Knüchel R; Dahl E
Epigenetics; 2018; 13(3):214-227. PubMed ID: 27623992
[TBL] [Abstract][Full Text] [Related]
8. Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC).
Storti CB; de Oliveira RA; de Carvalho M; Hasimoto EN; Cataneo DC; Cataneo AJM; De Faveri J; Vasconcelos EJR; Dos Reis PP; Cano MIN
Exp Mol Pathol; 2020 Feb; 112():104354. PubMed ID: 31837325
[TBL] [Abstract][Full Text] [Related]
9. SPC25 upregulation increases cancer stem cell properties in non-small cell lung adenocarcinoma cells and independently predicts poor survival.
Chen J; Chen H; Yang H; Dai H
Biomed Pharmacother; 2018 Apr; 100():233-239. PubMed ID: 29432994
[TBL] [Abstract][Full Text] [Related]
10. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
11. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
[TBL] [Abstract][Full Text] [Related]
12. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
[TBL] [Abstract][Full Text] [Related]
13. Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.
Liu X; Chen L; Zhang T
Cancer Control; 2018; 25(1):1073274818778001. PubMed ID: 29843532
[TBL] [Abstract][Full Text] [Related]
14. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognostic value of E2F activators in NSCLC and subtypes: a research based on bioinformatics analysis.
Gao Z; Shi R; Yuan K; Wang Y
Tumour Biol; 2016 Nov; 37(11):14979-14987. PubMed ID: 27655285
[TBL] [Abstract][Full Text] [Related]
16. [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].
Peng S; Li X; Liu Q; Zhang Y; Zou L; Gong X; Wang M; Ma X
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):641-649. PubMed ID: 31270041
[TBL] [Abstract][Full Text] [Related]
17. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
[TBL] [Abstract][Full Text] [Related]
18. Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma.
Qu Y; Zhang X; Qiao R; Di F; Song Y; Wang J; Ji L; Zhang J; Gu W; Fang Y; Han B; Yang R; Dai L; Ouyang S
Respir Res; 2024 Jan; 25(1):59. PubMed ID: 38273401
[TBL] [Abstract][Full Text] [Related]
19. Systematic analysis of IGF2BP family members in non-small-cell lung cancer.
Gong L; Liu Q; Jia M; Sun X
Hum Genomics; 2024 Jun; 18(1):63. PubMed ID: 38867248
[TBL] [Abstract][Full Text] [Related]
20. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
Liu B; Chen Y; Yang J
Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
